CD133 (Prominin-1) Monoclonal Antibody (13A4), Biotin, eBioscience™, Invitrogen™

Description

• Description: The 13A4 monoclonal antibody recognizes mouse Prominin-1 (sometimes also referred to as CD133 and, in the case of the human orthologue, as AC133), a 115-120 kDa pentaspan transmembrane (5-TM) domain glycoprotein
• Prominin-1 is expressed on primitive cells such as hematopoietic stem and progenitor cells, neural and endothelial stem cells, retina and retinoblastoma, as well as developing epithelium
• To date, the function and ligand of Prominin-1 are unknown
• The 13A4 antibody does not cross react with rat, human, chicken, or Drosophila antigen but has been reported to work in canine/dog
• Applications Reported: The 13A4 antibody has been reported for use in flow cytometric analysis
• It does not cross-react with rat and human Prominin-1
• Applications Tested: The 13A4 antibody has been tested by flow cytometric analysis of mouse bone marrow cells
• This can be used at less than or equal to 0.125 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Filtration: 0.2 μm post-manufacturing filtered
• The CD133 (AC133) antigen is a 97 kDa glycoprotein, with 5 transmembrane domains, that shows up as a 120 kDa band on protein gels due to glycosylation
• CD133 is a cell surface marker expressed by immature hematopoietic stem cells but not mature blood cells
• In addition to hematopoietic stem and progenitor cells, CD133 has been found to be a marker for other stem and progenitor cells including neural and embryonic stem cells
• CD133 has been shown to be expressed in cancers, including some leukemias and brain tumors, that may be derived from stem cells
• Low level expression could also be detected in the kidney, pancreas, placenta, and fetal liver
• Mutations in this gene have been shown to result in retinitis pigmentosa and Stargardt disease
• Expression of the CD133 gene is also associated with several types of cancer
• CD133 is expressed from at least five alternative promoters that are expressed in a tissue-dependent manner, and multiple transcript variants encoding different isoforms have been found.